The Drug Cell is born, a French Joint Venture poised to revolutionize the cell therapy sector. This groundbreaking project brings together technological and biotechnological excellence, including prominent companies, startups, universities, and leading research centers such as Carroucell, CECS/I-Stem (Centre for Stem Cell Studies), CHU of Montpellier, CHU of Rennes, EFS (French Blood Establishment), EVerZom, MGA Technologies, and the University of Montpellier.
GPI France, a subsidiary of the GPI Group, will play a pivotal role in the project by leading the development of advanced in silico models powered by artificial intelligence. These models will automate the production of cell therapies, making treatments for rare diseases more accessible and cost-effective.
The project is set to launch in May 2025, with the first clinical trials planned for 2030 and market entry anticipated by 2034. It represents a long-term initiative with a profound social impact, aiming to establish an independent European industrial supply chain to address future healthcare challenges with cutting-edge solutions.
As Sergio Manzana, future Chairman of The Drug Cell, explains: *“This project is a qualitative leap for GPI and a tangible response to the challenges of modern medicine. With The Drug Cell, we aim to improve people’s quality of life and push the boundaries of biomedicine.”*
